title: Multiple Genetic Analysis System-Based Antibiotic Susceptibility Testing in Helicobacter pylori and High Eradication Rate With Phenotypic Resistance-Guided Quadruple Therapy.
abstract: Antibiotics resistance in Helicobacter pylori (H. pylori) is the major factor for eradication failure. Molecular tests including fluorescence in situ hybridization, PCR-restriction fragment length polymorphism, and dual priming oligonucleotide-PCR (DPO-PCR) play critical roles in the detection of antibiotic susceptibility; however, limited knowledge is known about application of multiple genetic analysis system (MGAS) in the area of H. pylori identification and antibiotics resistance detection.The aim of this study is to determine the antibiotics resistance using different molecular tests and evaluate the treatment outcomes of E-test-based genotypic resistance.A total of 297 patients with dyspepsia complaint were recruited for gastroscopies. Ninety patients with H. pylori culture positive were randomly divided into 2 groups (test group and control group). E-test, general PCR, and MGAS assay were performed in test group. Patients in control group were treated with empirical therapy (rabeprazole + bismuth potassium citrate + amoxicillin [AMX] + clarithromycin [CLR]), whereas patients in test group received quadruple therapy based on E-test results twice daily for 14 consecutive days. The eradication effect of H. pylori was confirmed by C-urea breath test after at least 4 weeks when treatment was finished.Rapid urease test showed 46.5% (128/297) patients with H. pylori infection, whereas 30.3% (90/297) patients were H. pylori culture positive. E-test showed that H. pylori primary resistance rate to CLR, AMX, metronidazole, tetracycline, and levofloxacin (LVX) was 40.0% (18/45), 4.4% (2/45), 53.3% (24/45), 0% (0/45), and 55.6% (25/45), respectively. In addition, there are many multidrug resistant (MDR) phenotypes, and the MDR strains have higher minimum inhibitory concentration than their single-drug resistant counterparts. Considering E-test as the reference test, the sensitivities of general PCR and MGAS in detecting CLR resistance were 83.3% (15/18) and 94.4% (17/18), whereas in detecting LVX resistance were 100% (25/25) and 83.3% (15/18), respectively. Finally, the eradication rate in test group was significantly higher than that in control group as demonstrated by intention-to-treat analysis and per-protocol analysis.MGAS is a promising assay for H. pylori identification and antibiotic susceptibility testing. Phenotypic resistance-guided quadruple therapy showed a high efficacy in treating patients with H. pylori infection.
authors.affiliation: From the Department of Gastroenterology (FD, FZ, YH, ZB), Shanghai Key Laboratory of Clinical Geriatric Medicine; Department of Digestive Endoscopy Center (DJ, RH, PX), Huadong Hospital, Shanghai Medical College, Fudan University, Shanghai, PR China; and Ningbo HEALTH Gene Technologies Co., Ltd. (MK, LN, XZ, YW), Ningbo, PR China.
authors.forename: Fangyuan
authors.initials: F
authors.lastname: Dong
authors.forename: Danian
authors.initials: D
authors.lastname: Ji
authors.forename: Renxiang
authors.initials: R
authors.lastname: Huang
authors.forename: Fan
authors.initials: F
authors.lastname: Zhang
authors.forename: Yiqin
authors.initials: Y
authors.lastname: Huang
authors.forename: Ping
authors.initials: P
authors.lastname: Xiang
authors.forename: Mimi
authors.initials: M
authors.lastname: Kong
authors.forename: Li
authors.initials: L
authors.lastname: Nan
authors.forename: Xianping
authors.initials: X
authors.lastname: Zeng
authors.forename: Yong
authors.initials: Y
authors.lastname: Wu
authors.forename: Zhijun
authors.initials: Z
authors.lastname: Bao
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000145:classification / Q000494:pharmacology; D001944:Breath Tests / Q000379:methods; D016903:Drug Monitoring; D004352:Drug Resistance, Microbial / Q000235:genetics*; D004359:Drug Therapy, Combination / Q000379:methods; D004415:Dyspepsia / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D016680:Genome, Bacterial; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests / Q000379:methods; D008875:Middle Aged; D057285:Precision Medicine / Q000379:methods; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents